Elicera Therapeutics AB (publ) (STO:ELIC)
Sweden
· Delayed Price · Currency is SEK 5.74
-0.76 (-11.69%)
Mar 9, 2026, 5:29 PM CET
Elicera Therapeutics AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 24.85 | 26.4 | 29.38 | 43.82 | 52.39 | Upgrade
|
| Cash & Short-Term Investments | 24.85 | 26.4 | 29.38 | 43.82 | 52.39 | Upgrade
|
| Cash Growth | -5.88% | -10.15% | -32.95% | -16.36% | 353.04% | Upgrade
|
| Other Receivables | 2.57 | 0.88 | 0.34 | 0.33 | 0.2 | Upgrade
|
| Receivables | 2.57 | 0.88 | 0.34 | 0.33 | 0.2 | Upgrade
|
| Prepaid Expenses | - | 0.28 | 0.45 | 1.65 | 1.62 | Upgrade
|
| Other Current Assets | - | - | - | -0 | -0.01 | Upgrade
|
| Total Current Assets | 27.42 | 27.57 | 30.17 | 45.8 | 54.21 | Upgrade
|
| Long-Term Investments | - | 0 | 0 | 0.48 | 0.48 | Upgrade
|
| Other Intangible Assets | - | - | 0.01 | 0.02 | 0.04 | Upgrade
|
| Other Long-Term Assets | - | - | - | -0 | 0.01 | Upgrade
|
| Total Assets | 27.42 | 27.57 | 30.18 | 46.31 | 54.74 | Upgrade
|
| Accounts Payable | 2.57 | 2.04 | 0.88 | 0.73 | 2.05 | Upgrade
|
| Accrued Expenses | 1.24 | 4.4 | 12.5 | 12.53 | 0.31 | Upgrade
|
| Current Income Taxes Payable | - | - | - | 0.01 | 0 | Upgrade
|
| Other Current Liabilities | 0.25 | 0.35 | 0.4 | 0.24 | 0.14 | Upgrade
|
| Total Current Liabilities | 4.06 | 6.8 | 13.78 | 13.51 | 2.5 | Upgrade
|
| Total Liabilities | 4.06 | 6.8 | 13.78 | 13.51 | 2.5 | Upgrade
|
| Common Stock | 2.04 | 1.47 | 0.83 | 0.83 | 0.83 | Upgrade
|
| Additional Paid-In Capital | 106.06 | 86.62 | 66.79 | 66.79 | 66.79 | Upgrade
|
| Retained Earnings | -84.73 | -67.33 | -51.22 | -34.82 | -15.38 | Upgrade
|
| Comprehensive Income & Other | - | - | - | -0 | -0 | Upgrade
|
| Shareholders' Equity | 23.36 | 20.77 | 16.4 | 32.8 | 52.24 | Upgrade
|
| Total Liabilities & Equity | 27.42 | 27.57 | 30.18 | 46.31 | 54.74 | Upgrade
|
| Net Cash (Debt) | 24.85 | 26.4 | 29.38 | 43.82 | 52.39 | Upgrade
|
| Net Cash Growth | -5.88% | -10.15% | -32.95% | -16.36% | 353.04% | Upgrade
|
| Net Cash Per Share | 0.55 | 0.84 | 1.49 | 2.21 | 3.27 | Upgrade
|
| Filing Date Shares Outstanding | 48.54 | 35.09 | 19.78 | 19.78 | 19.78 | Upgrade
|
| Total Common Shares Outstanding | 48.54 | 35.09 | 19.78 | 19.78 | 19.78 | Upgrade
|
| Working Capital | 23.36 | 20.77 | 16.39 | 32.29 | 51.71 | Upgrade
|
| Book Value Per Share | 0.48 | 0.59 | 0.83 | 1.66 | 2.64 | Upgrade
|
| Tangible Book Value | 23.36 | 20.77 | 16.39 | 32.78 | 52.2 | Upgrade
|
| Tangible Book Value Per Share | 0.48 | 0.59 | 0.83 | 1.66 | 2.64 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.